TY - JOUR
T1 - Pharmacological Management of Chronic Rhinosinusitis
T2 - Current and Evolving Treatments
AU - Beswick, Daniel M.
AU - Gray, Stacey T.
AU - Smith, Timothy L.
N1 - Funding Information:
Conflict of interest Timothy L. Smith was previously a consultant for Intersect ENT. This relationship ended in 2015. He is supported by a grant for this investigation from the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, Bethesda, MD, USA (R01 DC005805; PI/PD: TL Smith). Public clinical trial registration (http://www. clinicaltrials.gov) ID: NCT01332136. This funding organization did not contribute to the design or conduct of this study; collection, management, analysis, or interpretation of the data; and preparation, review, approval or decision to submit this manuscript for publication.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Chronic rhinosinusitis (CRS) is an inflammatory sinonasal condition with multiple etiologic factors that is associated with a vast economic cost. Treatment is most frequently pharmacologic and has centered on agents that ameliorate inflammation, decrease bacterial or pathogen load, and facilitate egress of mucus or purulence from the sinonasal cavity. Nasal saline irrigations, topical nasal steroids, certain antibiotics, and systemic steroids have shown some efficacy in the management of CRS. Recently, biologic therapeutics that target specific inflammatory pathways associated with subsets of CRS have been developed and evaluated. Early data evaluating these biologic treatments suggest a potential role in treating a subset of CRS with refractory, poorly controlled disease. Additional studies are necessary to identify which patients would benefit most from biologic therapies and to assess the cost of these therapies compared with the benefit they provide. This review describes the pathophysiology of CRS and summarizes both established and novel biologic pharmacologic treatments.
AB - Chronic rhinosinusitis (CRS) is an inflammatory sinonasal condition with multiple etiologic factors that is associated with a vast economic cost. Treatment is most frequently pharmacologic and has centered on agents that ameliorate inflammation, decrease bacterial or pathogen load, and facilitate egress of mucus or purulence from the sinonasal cavity. Nasal saline irrigations, topical nasal steroids, certain antibiotics, and systemic steroids have shown some efficacy in the management of CRS. Recently, biologic therapeutics that target specific inflammatory pathways associated with subsets of CRS have been developed and evaluated. Early data evaluating these biologic treatments suggest a potential role in treating a subset of CRS with refractory, poorly controlled disease. Additional studies are necessary to identify which patients would benefit most from biologic therapies and to assess the cost of these therapies compared with the benefit they provide. This review describes the pathophysiology of CRS and summarizes both established and novel biologic pharmacologic treatments.
UR - http://www.scopus.com/inward/record.url?scp=85028769749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028769749&partnerID=8YFLogxK
U2 - 10.1007/s40265-017-0803-4
DO - 10.1007/s40265-017-0803-4
M3 - Article
C2 - 28853058
AN - SCOPUS:85028769749
SN - 0012-6667
VL - 77
SP - 1713
EP - 1721
JO - Drugs
JF - Drugs
IS - 16
ER -